Press Releases

Press Releases
Date Title and Summary View
Oct 19, 2017 Ozanimod highlighted in two oral presentations detailing results from phase III SUNBEAM™ and RADIANCE™ trials in RMS Additional clinical and non-clinical poster presentations will further characterize the profile of ozanimod SUMMIT, N.J.--(BUSINESS WIRE)-...
Oct 16, 2017 In the STEPSTONE open-label study, ozanimod demonstrated meaningful clinical and endoscopic improvements in patients with moderately to severely active Crohn's disease at week 12 In the TOUCHSTONE open-label extension study, ozanimod continued to demonstrate clinically meaningful results in modera...
Oct 2, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) will host a conference call and live audio webcast on Thursday, October 26, 2017 at 9 a.m. ET to discuss third quarter 2017 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgene.com. ...
Sep 8, 2017 Multiple presentations evaluate the investigational uses of ABRAXANE alone or as combination therapy to treat non-small cell lung cancer and as combination therapy for locally advanced pancreatic cancer BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced ...
Sep 7, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on five trials and a full clinical hold on one trial in the Celgene FUSION™ program. The trials are testing IMFINZI™ (durvalumab), an an...
Aug 24, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at four upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and will be available in the Investor Relations section of the Company's website at www.ce...
Aug 1, 2017 IDHIFA is the first and only oral, targeted inhibitor of IDH21 FDA approval of IDHIFA was based on results from the phase I/II AG-221 AML-001 study including safety, rate and duration of complete response (CR) or CR with partial hematologic recovery (CRh) and rate of conversion to transfusion inde...
Jul 28, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at an upcoming investor conference where Celgene management will provide an overview of the Company. The conference will be webcast live and will be available in the Investor Relations section of the Company's website at www.celgen...
Jul 27, 2017 - Strong Q2 performance; Updated 2017 EPS guidance - Positive ozanimod phase III data in relapsing multiple sclerosis (RMS) advances neuroscience franchise opportunities - Completed enrollment in five phase III trials during Q2, with data expected in 2018; Multiple phase III data r...
Jul 25, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that it has reached a civil settlement with Relator Brown, the Department of Justice, 28 States, the District of Columbia, and the City of Chicago to resolve the previously disclosed False Claims Act litigation pending in the United...
FirstPrevious
2
... NextLast
Add to Briefcase = add release to Briefcase